The mission of Case Comprehensive Cancer Center (Case CCC), now in its 25th year of NCI designation, is to promote a coordinated, translational research-oriented culture of scientific discovery applied to human cancers, with dissemination to patients and populations to improve cancer prevention, detection, treatment, cure, and survivorship. The Center provides leadership and oversight of collaboration for basic cancer research oriented toward identification of novel therapeutic targets;prevention, control and population research;therapeutic and non-therapeutic clinical research across the disease spectrum;and community outreach. The Center coordinates all aspects of cancer research in Cleveland and Northern Ohio, including activities of the affiliate institutions of Case Western Reserve University School of Medicine: Cleveland Clinic and University Hospitals. The Center provides opportunities to participate in clinical trials to almost 10,000 cancer patients who are newly diagnosed annually in the region. The opening in 2011 of the new freestanding cancer hospital, UH Seidman Cancer Center, and the funding of the Gl SPORE represent major achievements in this past grant cycle. The Case CCC is organized around 8 Scientific Programs, 15 shared resources, and a clinical and behavioral cancer research infrastructure that prioritizes innovative translational research and investigator-initiated clinical trials that ut across the Scientific Programs. The Case CCC includes 232 full members (335 total members) from 5 schools and 30 academic departments who actively participate in Cancer Center activities including Program and Core meetings and retreats, leadership committees, and scientific focus groups, each promoting a transdisciplinary approach that facilitates discovery and clinical application. The Cancer focus of the Center is exceptional, with over $116M in total funding and over $45M in total NCI funding. Institutional commitment is also exceptional with over $115M dedicated to cancer research in the next cycle and over $350M in construction anticipated. The Case CCC and its affiliate institutions have established an outstanding infrastructure that enables its members to improve the prevention, diagnosis, and treatment of cancer through discovery, implementation and dissemination, while providing state-of-the-art care and treatment to cancer patients and their families. The Case CCC is a significant partner with the NCI in its effort to change the practice of cancer care through discovery and clinical research of the highest quality.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA043703-23S2
Application #
8765484
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
23
Fiscal Year
2013
Total Cost
$37,026
Indirect Cost
$13,666
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Brown, Amanda L; Mark Brown, J (2017) Critical roles for ?/? hydrolase domain 5 (ABHD5)/comparative gene identification-58 (CGI-58) at the lipid droplet interface and beyond. Biochim Biophys Acta 1862:1233-1241
Thiagarajan, Praveena S; Zheng, Qiao; Bhagrath, Manvir et al. (2017) STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance. Endocr Relat Cancer 24:415-426
Yao, Peng; Wu, Jiangbin; Lindner, Daniel et al. (2017) Interplay between miR-574-3p and hnRNP L regulates VEGFA mRNA translation and tumorigenesis. Nucleic Acids Res 45:7950-7964
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
Doherty, Mary R; Cheon, HyeonJoo; Junk, Damian J et al. (2017) Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci U S A 114:13792-13797
Saygin, Caner; Wiechert, Andrew; Rao, Vinay S et al. (2017) CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. J Exp Med 214:2715-2732
Samaeekia, Ravand; Adorno-Cruz, Valery; Bockhorn, Jessica et al. (2017) miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. Clin Cancer Res 23:1091-1103
Flocke, Susan A; Hoffman, Richard; Eberth, Jan M et al. (2017) The Prevalence of Tobacco Use at Federally Qualified Health Centers in the United States, 2013. Prev Chronic Dis 14:E29
Balanis, Nikolas; Carlin, Cathleen R (2017) Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. Mol Cell Endocrinol 451:24-30
Johansen, Mette L; Gao, Ying; Hutnick, Melanie A et al. (2017) Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo. Anal Chem 89:5932-5939

Showing the most recent 10 out of 1182 publications